• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社区居住的阿尔茨海默病患者中,科恩-曼斯菲尔德激越量表与CERAD痴呆行为评定量表的比较。

A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease.

作者信息

Weiner M F, Koss E, Patterson M, Jin S, Teri L, Thomas R, Thal L J, Whitehouse P

机构信息

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75235-9070, USA.

出版信息

J Psychiatr Res. 1998 Nov-Dec;32(6):347-51. doi: 10.1016/s0022-3956(98)00027-2.

DOI:10.1016/s0022-3956(98)00027-2
PMID:9844950
Abstract

In a group of 242 community-dwelling patients with Alzheimer's disease (AD), a longitudinal comparison was made of two caregiver-administered instruments for assessment of behavioral disturbance; the Cohen-Mansfield Agitation Inventory (CMAI) and the CERAD Behavioral Rating Scale for Dementia (BRSD). We examined records of the 206 patients with baseline and 12-month follow-up data for the CMAI and the BRSD who also had tests of cognitive (Mini-mental State; MMSE) and global function (Clinical Dementia Rating; CDR and Functional Assessment Staging; FAST). Among 114 AD subjects, the correlation between total CMAI at baseline and 1 month readministration was 0.83 (p < 0.0001). In the same subjects, stratified into 5 groups by MMSE scores, the correlations between BRSD baseline and 1-month scores ranged from 0.70-0.89 (p < 0.0001). There was high correlation between total scores of both instruments at baseline and 12 months. In addition, all CMAI subscales except Verbally Aggressive correlated significantly with total BRSD score at both time points. At baseline, BRSD subscales for irritability/aggression, behavioral dysregulation and psychotic symptoms and at 12 months, irritability/aggression and behavioral dysregulation correlated with total CMAI scores. Neither scale changed significantly over 1 year, but there was wide individual variation. CMAI and BRSD scores correlated with 1-year change in the FAST, but not with MMSE or CDR (which weighs cognition heavily), suggesting that behavioral disturbance may be more strongly related to ability to manage activities of daily living (executive function) than to other aspects of cognition. The CMAI and BRSD appear to be interchangeable as measures of agitation, with the CMAI possibly more useful for patients who lack language and the BRSD more sensitive to apathy and depression.

摘要

在一组242名社区居住的阿尔茨海默病(AD)患者中,对两种由照料者实施的行为障碍评估工具进行了纵向比较;科恩 - 曼斯菲尔德激越量表(CMAI)和痴呆症的CERAD行为评定量表(BRSD)。我们检查了206名患者的记录,这些患者有CMAI和BRSD的基线及12个月随访数据,他们还进行了认知测试(简易精神状态检查表;MMSE)和整体功能测试(临床痴呆评定量表;CDR和功能评估分期;FAST)。在114名AD受试者中,基线时CMAI总分与1个月后再次施测的相关性为0.83(p < 0.0001)。在同一受试者中,按MMSE分数分层为5组,BRSD基线与1个月分数之间的相关性范围为0.70 - 0.89(p < 0.0001)。两种工具的总分在基线和12个月时具有高度相关性。此外,除言语攻击性子量表外,所有CMAI子量表在两个时间点与BRSD总分均显著相关。在基线时,BRSD的易怒/攻击、行为失调和精神病症状子量表以及在12个月时,易怒/攻击和行为失调与CMAI总分相关。两种量表在1年中均无显著变化,但个体差异较大。CMAI和BRSD分数与FAST的1年变化相关,但与MMSE或CDR(后者严重权衡认知)无关,这表明行为障碍可能与日常生活活动管理能力(执行功能)的关系比与认知的其他方面更强。作为激越的测量指标,CMAI和BRSD似乎可以互换,CMAI可能对缺乏语言能力的患者更有用,而BRSD对冷漠和抑郁更敏感。

相似文献

1
A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease.社区居住的阿尔茨海默病患者中,科恩-曼斯菲尔德激越量表与CERAD痴呆行为评定量表的比较。
J Psychiatr Res. 1998 Nov-Dec;32(6):347-51. doi: 10.1016/s0022-3956(98)00027-2.
2
Assessment of behavioral symptoms in community-dwelling dementia patients.社区居住型痴呆患者行为症状的评估
Am J Geriatr Psychiatry. 1997 Winter;5(1):26-30.
3
Quantifying behavioral disturbance in Alzheimer's disease patients.量化阿尔茨海默病患者的行为障碍。
J Psychiatr Res. 2000 Mar-Apr;34(2):163-7. doi: 10.1016/s0022-3956(99)00042-4.
4
Behavioral outcomes in clinical trials for Alzheimer disease.阿尔茨海默病临床试验中的行为学结果。
Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S10-5.
5
Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study.使用科恩-曼斯菲尔德激越量表评估阿尔茨海默病患者的激越模式。阿尔茨海默病协作研究。
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S45-50. doi: 10.1097/00002093-199700112-00007.
6
Agitation and aggression in people living with dementia and mild cognitive impairment in shared-housing arrangements - validation of a German version of the Cohen-Mansfield Agitation Inventory-Short Form (CMAI-SF).共居环境中痴呆和轻度认知障碍患者的激越和攻击行为 - 中文版 Cohen-Mansfield 激越量表短表(CMAI-SF)的验证。
Health Qual Life Outcomes. 2023 May 29;21(1):51. doi: 10.1186/s12955-023-02132-y.
7
Assessing Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications.使用科恩-曼斯菲尔德激越量表评估阿尔茨海默病患者:评分及临床意义
J Psychiatr Res. 2002 Jan-Feb;36(1):19-25. doi: 10.1016/s0022-3956(01)00047-4.
8
Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.使用 CERAD-NB 总分对阿尔茨海默病进行为期三年的随访:库奥皮奥 ALSOVA 研究。
Int Psychogeriatr. 2013 Aug;25(8):1335-44. doi: 10.1017/S1041610213000653. Epub 2013 May 16.
9
Validation of the Cohen-Mansfield Agitation Inventory Observational (CMAI-O) tool.验证 Cohen-Mansfield 激越观察量表(CMAI-O)工具。
Int Psychogeriatr. 2020 Jan;32(1):75-85. doi: 10.1017/S1041610219000279.
10
Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes research.临床上衍生的 MDS 量表在阿尔茨海默病结果研究中的有效性和对变化的反应性。
J Geriatr Psychiatry Neurol. 2011 Jun;24(2):67-72. doi: 10.1177/0891988711402347. Epub 2011 Apr 1.

引用本文的文献

1
Detecting agitation and aggression in persons living with dementia: a systematic review of diagnostic accuracy.检测痴呆患者的激越和攻击行为:诊断准确性的系统评价。
BMC Geriatr. 2024 Jun 26;24(1):559. doi: 10.1186/s12877-024-05143-6.
2
Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer's Dementia.系统评价中评估认知增强剂治疗阿尔茨海默病疗效的结果测量的有效性和可靠性的变异性。
PLoS One. 2019 Apr 18;14(4):e0215225. doi: 10.1371/journal.pone.0215225. eCollection 2019.
3
The Mahoney Pain Scale: examining pain and agitation in advanced dementia.
马奥尼疼痛量表:评估晚期痴呆症患者的疼痛与激越状态
Am J Alzheimers Dis Other Demen. 2008 Jun-Jul;23(3):250-61. doi: 10.1177/1533317508317524. Epub 2008 May 4.
4
Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease.社区居住的阿尔茨海默病患者精神病理学领域的共病情况。
J Geriatr Psychiatry Neurol. 2003 Jun;16(2):94-9. doi: 10.1177/0891988703016002006.